M. Boeckh, W. J. Murphy, and K. S. Peggs, Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies, Biol Blood Marrow Transplant, vol.21, issue.2, pp.19-24, 2015.

M. Boeckh and W. G. Nichols, The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy, Blood, vol.103, issue.6, pp.2003-2011, 2004.

P. Teira, M. Battiwalla, and M. Ramanathan, Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis, Blood, vol.127, issue.20, pp.2427-2465, 2016.

M. Pollack, J. Heugel, and H. Xie, An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients, Biol Blood Marrow Transplant, vol.17, issue.5, pp.664-73, 2011.

M. Boeckh, T. A. Gooley, D. Myerson, T. Cunningham, G. Schoch et al., Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study, Blood, vol.88, issue.10, pp.4063-71, 1996.

J. M. Goodrich, R. A. Bowden, L. Fisher, C. Keller, G. Schoch et al., Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant, Ann Intern Med, vol.118, issue.3, pp.173-181, 1993.

D. J. Winston, W. G. Ho, and K. Bartoni, Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial, Ann Intern Med, vol.118, issue.3, pp.179-84, 1993.

P. Reusser, J. G. Gambertoglio, K. Lilleby, and J. D. Meyers, Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients, J Infect Dis, vol.166, issue.3, pp.473-482, 1992.

F. M. Marty, P. Ljungman, and G. A. Papanicolaou, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, Lancet Infect Dis, vol.11, issue.4, pp.284-92, 2011.

F. M. Marty, D. J. Winston, and S. D. Rowley, CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation, N Engl J Med, vol.369, issue.13, pp.1227-1263, 2013.

R. F. Chemaly, A. J. Ullmann, and S. Stoelben, Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation, N Engl J Med, vol.370, pp.1781-1790, 2014.

M. A. Kharfan-dabaja, M. Boeckh, and M. B. Wilck, A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Infect Dis, vol.12, issue.4, pp.290-299, 2012.

R. Nakamura, L. Rosa, C. Longmate, and J. , Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial, Lancet Haematol, vol.3, issue.2, pp.87-98, 2016.

P. T. Ljungman, R. F. Chemaly, and J. A. Maertens, A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Letermovir (LET) for Prevention of Cytomegalovirus (CMV) Infection in Adult CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT), 43rd Annual Meeting of the European Blood and Marrow Transplantation Group, 2017.

A. H. Filipovich, D. Weisdorf, and S. Pavletic, National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-host disease: I. Diagnosis and staging working group report, Biol Blood Marrow Transplant, vol.11, issue.12, pp.945-56, 2005.

H. Glucksberg, R. Storb, and A. Fefer, Clinical manifestations of graft-versushost disease in human recipients of marrow from HLA-matched sibling donors, Transplantation, vol.18, issue.4, pp.295-304, 1974.

D. Przepiorka, D. Weisdorf, and P. Martin, Consensus conference on acute GVHD grading, Bone Marrow Transplant, vol.15, issue.6, pp.825-833, 1994.

, Transplantation ESfBaM: MED-AB FORMS MANUAL: A guide to the completion of the EBMT HSCT Med-AB forms, 2010.

P. Ljungman, P. Griffiths, and C. Paya, Definitions of cytomegalovirus infection and disease in transplant recipients, Clin Infect Dis, vol.34, issue.8, pp.1094-1101, 2002.

P. Ljungman, R. De-la-camara, and C. Cordonnier, Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT, Bone Marrow Transplant, vol.42, issue.4, pp.227-267, 2008.

J. Zaia, L. Baden, and M. Boeckh, Viral disease prevention after hematopoietic cell transplantation, Bone Marrow Transplant, vol.44, pp.471-82, 2009.

N. Khera, A. Emmert, B. Storer, B. Sandmaier, E. Alyea et al., Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens, Oncologist, vol.19, pp.639-683, 2014.

S. J. Lee, N. Klar, J. C. Weeks, and J. H. Antin, Predicting costs of stem-cell transplantation, J Clin Oncol, vol.18, issue.1, pp.64-71, 2000.

A. M. Saito, C. Cutler, and D. Zahrieh, Costs of allogeneic hematopoietic cell transplantation with high-dose regimens, Biol Blood Marrow Transplant, vol.14, issue.2, pp.197-207, 2008.

A. M. Saito, D. Zahrieh, and C. Cutler, Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy, Bone Marrow Transplant, vol.40, issue.3, pp.209-226, 2007.

M. Van-agthoven, M. T. Groot, and L. F. Verdonck, Cost analysis of HLAidentical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia, Bone Marrow Transplant, vol.30, issue.4, pp.243-51, 2002.

H. Esperou, A. Brunot, and F. Roudot-thoraval, Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective multicenter, French study Transplantation, vol.77, issue.12, pp.1854-1862, 2004.

R. I. Griffiths, E. B. Bass, N. R. Powe, G. F. Anderson, S. Goodman et al., Factors influencing third party payer costs for allogeneic BMT, Bone Marrow Transplant, vol.12, issue.1, pp.43-51, 1993.

N. A. Jain, K. Lu, and S. Ito, The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches, Cytotherapy, vol.16, issue.7, pp.927-960, 2014.

A. E. Broers, R. Van-der-holt, and J. W. Van-esser, Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation, Blood, vol.95, issue.7, pp.2240-2245, 2000.

T. Bontant, P. Sedlacek, and A. Balduzzi, Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT, Bone Marrow Transplant, vol.49, issue.2, pp.276-285, 2014.

J. Schelfhout, H. Brown, and J. House, Cost of hematopoietic stem cell transplant and cytomegalovirus-related complications in a large inpatient claims database. California: Infectious Diseases Week San Diego, pp.4-8, 2017.

M. Boeckh, W. G. Nichols, and R. F. Chemaly, Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial, Ann Intern Med, vol.162, issue.1, pp.1-10, 2015.

C. J. Saret, A. N. Winn, and G. Shah, Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses, Blood, vol.125, issue.12, pp.1866-1875, 2015.